7-(5-tert-butoxycarbonyl-4-methylindan-1-(S)-ylcarbamoyl)pyrazolo[1,5-a]pyrimidine-5-carboxylic acid 5-methyl ester | 916212-34-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并嘧啶类
• 英文名称: 7-(5-tert-butoxycarbonyl-4-methylindan-1-(S)-ylcarbamoyl)pyrazolo[1,5-a]pyrimidine-5-carboxylic acid 5-methyl ester
• 英文别名: methyl 7-[[(1S)-4-methyl-5-[(2-methylpropan-2-yl)oxycarbonyl]-2,3-dihydro-1H-inden-1-yl]carbamoyl]pyrazolo[1,5-a]pyrimidine-5-carboxylate
• CAS: 916212-34-5
• 化学式: C₂₄H₂₆N₄O₅
• 分子量: 450.494
• InChiKey: VWAIPWQZBGFOME-KRWDZBQOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  33
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  112
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  7-(5-tert-butoxycarbonyl-4-methylindan-1-(S)-ylcarbamoyl)pyrazolo[1,5-a]pyrimidine-5-carboxylic acid 5-methyl ester 在 水 、 lithium hydroxide 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 以100%的产率得到7-(5-tert-butoxycarbonyl-4-methyl-indan-1-(S)-yl-carbamoyl)pyrazolo[1,5-a]pyrimidine-5-carboxylic acid
  参考文献：
  名称：

  Discovery and Evaluation of a Non-Zn Chelating, Selective Matrix Metalloproteinase 13 (MMP-13) Inhibitor for Potential Intra-articular Treatment of Osteoarthritis

  摘要：

  Osteoarthritis (OA) is a nonsystemic disease for which no oral or parenteral disease-modifying osteoarthritic drug (DMOAD) is currently available. Matrix metalloproteinase 13 (MMP-13) has attracted attention as a target with disease-modifying potential because of its major role in tissue destruction associated with OA. Being localized to one or a few joints, OA is amenable to intra-articular (IA) therapy, which has distinct advantages over oral therapies in terms of increasing therapeutic index, by maximizing drug delivery to cartilage and minimizing systemic exposure. Here we report on the synthesis and biological evaluation of a non-zinc binding MMP-13 selective inhibitor, 4-methyl-1-(S)-({5-[(3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-ylmethyl)carbamoyl]pyrazolo[1,5-a]pyrimidine-7-carbonyl}amino)indan-5-carboxylic acid (1), that is uniquely suited as a potential IA-DMOAD: it has long durability in the joint, penetrates cartilage effectively, exhibits nearly no detectable systemic exposure, and has remarkable efficacy.

  DOI：

  10.1021/jm201152u
• 作为产物：
  描述：

  乙酰丙酮酸甲酯 在 N-甲基吗啉 、 叔丁基过氧化氢 、 selenium(IV) oxide 、 potassium peroxymonosulfate 、 N-羟基-7-氮杂苯并三氮唑 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 1,4-二氧六环 、 甲醇 、 癸烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 93.0h， 生成 7-(5-tert-butoxycarbonyl-4-methylindan-1-(S)-ylcarbamoyl)pyrazolo[1,5-a]pyrimidine-5-carboxylic acid 5-methyl ester
  参考文献：
  名称：

  Discovery and Evaluation of a Non-Zn Chelating, Selective Matrix Metalloproteinase 13 (MMP-13) Inhibitor for Potential Intra-articular Treatment of Osteoarthritis

  摘要：

  Osteoarthritis (OA) is a nonsystemic disease for which no oral or parenteral disease-modifying osteoarthritic drug (DMOAD) is currently available. Matrix metalloproteinase 13 (MMP-13) has attracted attention as a target with disease-modifying potential because of its major role in tissue destruction associated with OA. Being localized to one or a few joints, OA is amenable to intra-articular (IA) therapy, which has distinct advantages over oral therapies in terms of increasing therapeutic index, by maximizing drug delivery to cartilage and minimizing systemic exposure. Here we report on the synthesis and biological evaluation of a non-zinc binding MMP-13 selective inhibitor, 4-methyl-1-(S)-({5-[(3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-ylmethyl)carbamoyl]pyrazolo[1,5-a]pyrimidine-7-carbonyl}amino)indan-5-carboxylic acid (1), that is uniquely suited as a potential IA-DMOAD: it has long durability in the joint, penetrates cartilage effectively, exhibits nearly no detectable systemic exposure, and has remarkable efficacy.

  DOI：

  10.1021/jm201152u

文献信息

• Heterobicyclic metalloprotease inhibitors
  申请人：Gallagher M. Brian

  公开号：US20070155737A1

  公开（公告）日：2007-07-05

  The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic ADAMTS-4 inhibiting compounds.

  本发明通常涉及含有酰胺基团的药物，特别是含有酰胺基团的杂双环金属蛋白酶抑制剂化合物。更具体地，本发明提供了一类新的杂双环ADAMTS-4抑制剂化合物。
• HETEROBICYLIC METALLOPROTEASE INHIBITORS
  申请人：Alantos Pharmaceuticals, Inc.

  公开号：EP2038284A2

  公开（公告）日：2009-03-25
• Heterobicyclic Metalloprotease Inhibitors
  申请人：STEENECK Christoph

  公开号：US20090312312A1

  公开（公告）日：2009-12-17

  The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
• HETEROBICYCLIC METALLOPROTEASE INHIBITORS
  申请人：Steeneck Christoph

  公开号：US20120015920A1

  公开（公告）日：2012-01-19

  The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
• US7795245B2
  申请人：——

  公开号：US7795245B2

  公开（公告）日：2010-09-14